Day 2 :
Keynote Forum
Eugenie Bergogne Berezin
Paris University, France
Keynote: Chronicle of EBOLA epidemics (2017): The return of EBOLA
Biography:
Eugenie Bergogne-Berezin is a Professor of Clinical Microbiology at University Diderot, Paris. She has studied MD in Medicine and PhD in Sciences in the early 1970s. She is a Chief of Department of Clinical Microbiology and research group, University Bichat Claude-Bernard and developed research on Acinetobacter spp., (nosocomial pathogen, pathogenicity, resistance), pharmacology of antibiotics, tissue distribution (lungs, brain, bronchi), research on intestinal ecology, jejunal flora and bacterial adhesion. She is an Adviser to pharmaceutical companies, expert in pharmacology-toxicology for the Ministry of Health, expert for international journals. She has developed a journal Antibiotics, (Elsevier). She has published 6 medical books, many chapters in international infectious diseases books, 200 articles in scientific journals.
Abstract:
2014,17,01, an Editorial entitled “Planetary viral extension” underlined the insufficient attention of Occidental Countries to the 20 EBOLA epidemics within 30 years, with 9936 cases and 4877 deaths. Guinea, Liberia, Sierra Leone were the most contaminated populations. Starting in Guinea WHO announced 2000 deaths. A French investigation published in 2007 had described a blaze-off epidemics only in 1995 in Kinshasa West with 250 deaths. Since then a brutal development of the disease extremely contagious has gained a rapid geographical extension in all Sub-Saharan Africa, Zaire, Soudan as well as West African countries. A worldwide interest in the disease (the journal TIME in 2014 “now arriving the deadly Ebola virus lands in America” (death was waiting for the traveler). Four major analyzes: (a) Epidemiology: including local surveillance, containment measures, WHO and journals of instant information. (b) Measures Since 2007: CDC-Mobile laboratories, surveillance of suspects or alerts or probable (febrile or hemorrhagic or deaths cases) (immediately notified). (c) The office of “rumors” (news) (WHO: gloves, javel, mosquitos). Ebola is transmitted directly by contact, imposing the “salut EBOLA” (EBOLA fistful). (d) Funerals major source of contamination with traditional cleaning, embalms in close contact with the body and family members. Containment, surveillance, education, hygiene, medical personnel are current. WHO “Staff at the outbreak sites see evidence that the nimbers of reported cases and deaths underestimate the magnitude of the outbreak.”
Keynote Forum
Stef Stienstra
Royal Dutch Navy, The Netherlands
Keynote: Investing in public health gives especially in low income countries extremely impressive returns
Biography:
Dr. Stef Stienstra works internationally for several medical and biotech companies as the scientific advisory board member and is also an active reserve-officer of the Royal Dutch Navy in his rank as Commander (OF4). For the Dutch Armed Forces, he is CBRN specialist with the focus on (micro)biological and chemical threats and medical- and environmental functional specialist within the 1st CMI (Civil-Military Interaction) Battalion of the Dutch Armed Forces. For Expertise France he is now managing an EU CBRN CoE public health project in West Africa. He is visiting professor for the University of Rome Tor Vergata in Italy for the CBRN Masters Course and lecturer for the NATO School in Oberammergau in Germany and the Joint NATO CBRN-Defense Center of Excellence in Vyskov in the Czech Republic. In his civilian position, he is at this moment developing with MT-Derm in Berlin (Germany) a novel intradermal vaccination technology as well as a new therapy for cutaneous leishmaniasis for which he has won a Canadian ‘Grand Challenge’ grant. With Hemanua in Dublin (Ireland) he has developed an innovative blood separation unit, which is also suitable to produce convalescent plasma for Ebola Virus Disease therapy. He has finished both his studies in Medicine and in Biochemistry in The Netherlands with a doctorate and has extensive practical experience in cell biology, immuno-hematology, infectious diseases, biodefense, and transfusion medicine. His natural business acumen and negotiation competence help to initiate new successful businesses, often generated by unexpected combinations of technologies.
Abstract:
The implementation of the International Health Regulation (IHR) of WHO in 2005 for worldwide public health systems is already in its second extension phase. At the 2012 deadline, only 16% of the countries were fully prepared to detect and respond to pandemics. In 2014 the Ebola Virus Disease outbreak in West Africa was another indicator that WHO’s IHR has to be taken seriously. Especially the biosecurity part of IHR is not fully in place yet for most developing countries, which makes the world vulnerable for bioterrorism. According to the World Bank, the returns from investing in public health are extremely impressive and is not a high-risk venture as with a rapid mortality decline many ‘value life years’ (VLYs) are gained. For low- and middle-income countries typically about a quarter of the growth in full income resulted from VLYs gained and supports not only the local economy but also the world economy. Therefore several international programs help to prepare low- and middle-income countries to mitigate outbreaks of infectious diseases. EU CBRN CoE initiatives and the US CBEP, DTRA, CTR, GEIS, DIMO, USAID, PEPFAR and several other programs are involved in establishing public health systems and give local healthcare workers training in both disease outbreak mitigation and biosecurity. Zoonotic diseases are the most dangerous for outbreaks as the population does not have natural or artificial (from vaccination) immune response to new emerging diseases. Zoonotic diseases are often neglected in the first instance in developing countries. The recent Ebola Virus Disease outbreak in West Africa was such an example. Still, there is hope to find fast and supportive therapies with proper blood bank facilities in place. The therapy with immunoglobulins obtained from plasma donations from survivors is a relatively cheap and effective therapy. International there was some criticism of this method, as for this therapy it is extremely important that the convalescent plasma has to be safe for other blood transmissible diseases. But as it is feasible with other convalescent plasma therapies, the necessary safety tests can be done in the laboratories, which are installed for the outbreak diagnosis. Convalescent plasma can be obtained from a donor, who has survived the disease, with a novel hollow fiber blood separation technology. This results in an immunoglobulin concentration, which does not need for its production any sophisticated infrastructure. This patented and recently developed disposable device is developed in cooperation with the Irish Blood Transfusion Service.
Dr. Stef Stienstra works internationally for several medical and biotech companies as the scientific advisory board member and is also an active reserve-officer of the Royal Dutch Navy in his rank as Commander (OF4). For the Dutch Armed Forces, he is CBRN specialist with the focus on (micro)biological and chemical threats and medical- and environmental functional specialist within the 1st CMI (Civil-Military Interaction) Battalion of the Dutch Armed Forces. For Expertise France he is now managing an EU CBRN CoE public health project in West Africa. He is visiting professor for the University of Rome Tor Vergata in Italy for the CBRN Masters Course and lecturer for the NATO School in Oberammergau in Germany and the Joint NATO CBRN-Defense Center of Excellence in Vyskov in the Czech Republic. In his civilian position, he is at this moment developing with MT-Derm in Berlin (Germany) a novel intradermal vaccination technology as well as a new therapy for cutaneous leishmaniasis for which he has won a Canadian ‘Grand Challenge’ grant. With Hemanua in Dublin (Ireland) he has developed an innovative blood separation unit, which is also suitable to produce convalescent plasma for Ebola Virus Disease therapy. He has finished both his studies in Medicine and in Biochemistry in The Netherlands with a doctorate and has extensive practical experience in cell biology, immuno-hematology, infectious diseases, biodefense, and transfusion medicine. His natural business acumen and negotiation competence help to initiate new successful businesses, often generated by unexpected combinations of technologies.
Keynote Forum
Ivana Haluskova Balter
French society of immunology, France
Keynote: Tackling neglected diseases in current context
Biography:
Haluskova Balter Ivana , MD,MBA, France, French/Slovak active medical professional specialised in infectious diseases, internal medicine covering various therapeutic axes, certified in Immunology and Pediatric, MBA in vaccinology. Lived multi-country medical “field “experience in Southeast Asia, West/Central/East Europe and Middle East. Speaking French, English, Russian, Italian, Czech, and Slovak with notion of Mandarin. Over 15 years of experience in pharmaceutical research and development for European and USA companies as Medical lead /Director of R&D in various therapeutic areas and as Scientific and Medical independent consultant for various academic and private stakeholders globally. Active member of French immunology society (SFI) administrative board and several international academic societies with focus on R&D innovation and partnership highlighting role immunology/immune-metabolism and genetics for innovative treatment, prevention and diagnostic. Member of advisory Health concern (India) and think tank group in order to attract attention to role of accessible medical care, education and awareness along with accurate diagnostic and innovative partnership in this area. Years of expertise to work globally but recently more focused on BRICS as Medical advisor for scientific partnership, bringing new innovative concepts alive and getting them endorsed.
Abstract:
The fight against the Neglected Tropical Diseases receiving increased worldwide attention after the recent attribution of the 2015 Nobel Prize in Physiology or Medicine to William Campbell and Satoshi ÅŒmura for their development of a novel therapy against infections caused by roundworm parasites. Neglected tropical diseases (NTDs) known to be a diverse and growing group of communicable diseases that prevail in tropical and subtropical conditions in 149 countries affect more than one billion people and cost developing economies billions of dollars every year. Populations living in poverty, without adequate sanitation and in close contact with infectious vectors and domestic animals and livestock are those worst affected. Despite encouraging progress, millions of people still need free high-quality treatments and millions more still need care and treatment for human dog-mediated rabies, echinococcosis, leishmaniasis and other neglected tropical diseases seemingly difficult to treat. Neglected tropical diseases program in global manner encompass biology of parasites and their vectors. Its research program addresses global public health concerns in terms of disease prevention, control and antiparasitic treatment. Along with understanding of the dynamic interactions between these microorganisms and their hosts, identifying the fundamental bases of parasitism and transmission by vectors, host invasion mechanisms, and determine parasite factors underlying virulence and pathology of these organisms. From scientific point of view, tackling infectious and tropical disease encompass various aspects including like transmission mechanisms, virulence factors, pathogens reservoirs, host immune response working transversally through epidemiology , microbiology, genetics and genomics, cell biology, biochemistry and bioinformatics and imaging. Apart vector born diseases like Dengue and Zika recent research in France look particularly on three key eukaryotic pathogens responsible for severe parasitic diseases that have a significant health and economic impact and affect most of the world’s population: Plasmodium the causative agent of malaria, Leishmania – the agent of leishmaniasis, and Trypanosoma brucei – responsible for sleeping sickness. The Anopheles mosquito, which is the vector of Plasmodium and a number of arboviruses, is being studied along with the tsetse fly, the vector of African trypanosomiasis. Fundamental research on in vitro and in vivo models – including ï¬eld work in Africa, Asia, South America – with applied research on resistance to antimalarial drugs and on the discovery of new antiparasitic drugs include exploration of traditional medicine and methods like reverse pharmacology.Accurate diagnostic and surveillance with better understanding of genetic and immunologic background of host specific response and pathogen evolution drives adapted vaccine research but also preventive interventions. As one of examples to illustrate it, global mapping of resistance to artemisinin (the KARMA study driven by Institut Pasteur in Paris and the Institut Pasteur in Cambodia and members of Institut Pasteur International Network) monitoring risk of spread of artemisine resistance from Asia to Africa using discovery of kelch(K13)–propeller domains as the primary determinant of artemisinin resistance. Immunology is relatively new science about composition, functions, reaction of immune system. Host immune system co-evolute with pathogens and commensal microbiota given individual genetic predispositions and variability and remains along with neuroendocrine system one of the key to maintain homeostasis of organism. Knowledge in immunology is growing and providing clinically valuable solutions across various for diagnostic, preventive (innovative vaccination ) and treatment strategies including neglected and tropical diseases. Based on works natural defences to infection are mediated by intrinsic/innate and adaptive immune responses. Understanding the role of early metabolic mediators of inflammatory responses to infection and principles of immuno-metabolism expect to help in the development of urgently needed host directed therapeutic, preventive (vaccines) and diagnostic innovations knowing limitations of existing tools.
Location: Boston,USA
Session Introduction
El-Gawadi HM
Suez Canal University, Egypt
Title: Serological and molecular studies on Toxoplasma gondii infection in Sheep and Goats in Ismailia Province, Egypt
Biography:
Abstract:
Blood serum samples from 100 sheep and 100 goats were collected and examined for Toxoplasma gondii antibodies by Enzyme-Linked Immunosorbent Assay and Modified Agglutination Test. The seroprevalences of Toxoplasma gondii in sheep were 34% and 33% and in goats were 32%, 31% by ELISA and MAT respectively. The prevalence in the females of sheep and goats were higher than males. The seroprevalences were higher in adult animals than young in both sheep and goats. Using the MAT as a reference test, the sensitivity and specificity of the ELISA Test were 100% and 98.5% respectively. Diagnosis of Toxoplasma gondii in 20 brain samples ( 10 from sheep and 10 from goats) using nested PCR techniques by amplification of the T. gondii B1 gene revealed that six sheep's brain samples were positive (60%) and six goat's brain samples were positive (60%). The bioassay was done by inoculation of T. gondii positive PCR samples into healthy mice. Histopathological examination of the experimental mice brains declared pathological lesions with a demonstration of pseudocysts containing bradyzoites within the host cell cytoplasm in the mice killed a 30th day and 35th day post inoculation.
Simon Raymond
Alumnus Melbourne University, Austrelia
Title: Site attachment inhibition therapeutics: Progress update
Biography:
Simon Raymond is a Consultant who specialized in Medical and Scientific Research and an Alumnus of Melbourne University (Rank of Number 1 in Australia and Number 33 in the World). The above stated Researcher has acted as a Reviewer for the respected Medical Journal of Australia, has received invitations internationally to review from prestigious medical journals including the Journal of American Medical Association Network. He has received the award in recognition of his research by Royal Australasian College of Surgeons (PSC, 2006) and invited to conferences internationally as an official Delegate and Researcher, including that in USA and China. He has worked as the Principal Researcher in the highest-powered form of medical trial-Randomized Controlled Trial (RCT). The above stated Researcher is also a Member of the Golden Key International Society for Honored and outstanding Academics and has been cited as a Notable Global Leader.
Abstract:
The current researcher has in previous conferences and publications detailed the conceptualization and development of the new, or third, branch of antimicrobial therapeutics, namely site attachment inhibition which involves negation of cellular attachment by infective agents. This based on the issues with metaphorical superbugs, development of antimicrobial resistance, and the general lack of success currently with respect to the previous two branches which focused on (1) replication of infective agent and, (2) immune system enhancement. This talk explains that site attachment inhibition is intended to consist of both treatment of established infection but also new generation immunization programs. The likely success of new generation immunization programs, based on prenatal stem cell therapy is intended to involve gene mutagenesis or knockout. This preventative (or, immunization) therapy intended to be spanning right back to spermatogenesis and oogenesis. The validation for likely success includes the innate resistance or immunity achieved by inherited genetic mutations, including CCR5-Δ32 against HIV. One major issue is a differentiation between association and causation. Even the known CCR5-Δ32 mutation has not been completely confirmed as direct/causative of the inhibition of attachment observed in research analyses. New content presented in this talk will involve methods around the above issues to do with association and causation. These methods include the use of CRISPR technology in order to analyze properly the genes (and, methods) utilized by those with innate resistance (immunity) in order to determine the proper prenatal genetic therapy, as mentioned above, in new generation immunization programs. Prenatal genetic therapy is becoming increasingly discussed and utilized in medicine and surgery. However, an important issue remains the ethics committee and community consideration in such treatment strategy consideration.
Ayat Zawawi
The University of Manchester, UK
Title: Towards the development of a novel vaccine for Trichuris trichiura
Biography:
Ayat Zawawi is a PhD student at the University of Manchester. She is a Lecturer at King Abdul-Aziz University in Jeddah, KSA, Faculty of Applied Medical Sciences.
Abstract:
Trichuris trichiura (whipworm) is a soil-transmitted helminth parasite that affects around 500 million people worldwide, resulting in disability and poor child development, especially in areas of poor hygiene and sanitation. The ideal vaccine to protect against T. trichiura in humans would include protein epitopes that elicit a protective T helper cell type 2 immune response. Herein, we used bioinformatics tools to identify candidate histocompatibility complex class II (MHC-II) molecule T cell epitopes from known Trichuris muris proteins selected using inclusion and exclusion criteria. T. muris is the murine whipworm that is closely related to the human pathogen making it a relevant model parasite. A number of prediction tools are available for the identification of peptides that bind to MHC II molecules. The lack of standardized methodology and the difficulty of MHC II epitope prediction make the selection of an appropriate prediction tool difficult. This study reports a systematic review to choose the most appropriate tools to predict MHC II epitopes. Subsequently, up to fifteen epitopes were predicted, from the selected T. muris proteins and expressed on Hepatitis B core antigen virus-like particles (HBc-Ag). HBc+ T cell epitopes were tested in vitro to address whether they activate antigen presenting cells. We also immunized normally susceptible mice with the HBc+ T cell epitopes prior to infection with T. muris to test the protective immune response in vivo. The predicted epitopes identified using the right combination of immunoinformatics and immunogenicity screening tools have the potential to bring T. trichiura to vaccine trial.
Hanaa A. Siam
National Public Health Laboratory, Sudan
Title: Effectiveness of Community-based Dengue Vector Control: Trial in Kassala City- Eastern Sudan.
Biography:
Hanaa Adli Siam, a scientific researcher in Department of Medical Entomology – National Public Health Laboratory –Federal Ministry of Health – Sudan, since 2012. She has a Master degree in Medical Entomology and vector control from Faculty of Science - University of Khartoum 2010. She has two published papers and participated in about ten international conferences and workshops.
Abstract:
Dengue is becoming an endemic disease in Eastern Sudan with repeated outbreaks during last two decades. This study aimed to investigate an effective method for community participation in dengue vector control (Aedesaegypti) in Kassala city. The study was conducted during May to December 2011. A cluster was composed in eight neighborhood; each cluster was formed of three grouped houses. One of these grouped houses was allocated randomly into one of three study arms: arm1 intervention of community volunteers; arm 2: intervention of house holder education and arm 3: Control. In arm 1, sixteen volunteers (two per cluster) inspected the water containers of houses weekly. In the house hold arm 2, householders received two educational sessions for breeding site of vectors source elimination and management of their water containers. In the control arm, houses did not receive any interventions. Bimonthly Entomological survey was conducted for eight months in each cluster of the study. The covering situation of inspected water containers was also recorded. From 9537 inspected containers, 545(5.71%) containers were found positive for aquatic stages of Aedes. aegypti. Zieers (localwater containers) composed 436 (80%) from the positive containers. ANOVA analyses were done between the three arms and no significant differences were found. Those entomological indices declined in community volunteers and householders arms. Also, the percentage of covering Zieers increased from 14.1% to 64.7% in community volunteer’s arm and from 12.1% to 32.6% in house holder arm. In control arm there was a fluctuation in all parameters. The arm of Community volunteers may be more effective in increasing the awareness of covering containers and decline of the entomological indices. Thus, it may be used as an approach for community participation in Dengue vector control in Kassala city.
Samer M Al-Hulu
Al-Qasim Green University, Iraq
Title: Some notes about medical applications for bacterial siderophore
Biography:
Samer M Al-Hulu, Assistant Professor of Microbiology, has completed his PhD from Babylon University/College of Science-Iraq. He has published more than 14 papers in microbiology field. Al-Hulu, has training at Ministry of Health at Laboratory of Babylon Maternity and Children Hospital. Now working at Al-Qasim Green University/College of Food Science-Iraq.
Abstract:
Statement of the problem: Some diseases need to treating by iron and some elements removing which achieved by production of bacterial siderophore.
Methodology & Theoretical Orientation: Under the iron-restricted condition many bacteria produced iron-chelating molecules called siderophore. Siderophore chelate iron and supply to the bacterial cell by outer membrane receptors. There are three main types of siderophores known as hydroxamate, catecholate, and carboxylate. It having many medical application, includes iron overload diseases treatment, such as ß-thalassemia. In the treatment of ß -thalassemia and certain other anemias, siderophores used as chelating agents, which having ability to bind with iron to produce complexes that lead to formation of ferrioxamine. The ferrioxamine is soluble in water and readily excreted through the kidneys. It binds with iron in the blood and enhances its elimination via urine and faeces, Selective Drug Delivery-Trojan horse strategy (Siderophore-antibiotic conjugates–Sideromycins, It can be used for selective delivery of antibiotics in antibiotic-resistant bacteria. Antimalarial Activity, Desferrioxamine B produced by Streptomyces pilosus used for the treatment of malaria caused by Plasmodium falciparum. Siderophores used for removing some elements from the body such as Aluminium overload, which occurs in dialysis encephalopathy, Vanadium removal, Desferal can be used for removal of vanadium from the body. Iron chelators in the treatment of cancers e.g. Dexrazoxane. Also used for the clearance of non-transferrin bound iron in serum which occurs in cancer therapy as a result of some chemotherapies. Iron chelation therapy may be useful against malignant cells without any significant cytotoxicity on nonmalignant cells. Siderophore has an ability to chelate various other metal ions which paved a way to concentrate the application of siderophore towards wound care products. Deodorant–Siderophore for Klebsiella pneumonia has been used in cosmetics as deodorant.
Findings: Using siderophore having an important role in disease treatment and other medical applications.
Conclusion & Significance: There are many medical applications for siderophore includes, Iron overload diseases treatment, Selective Drug Delivery, Antimalarial Activity, as Iron chelation therapy, as wound care products, also used in cosmetics as a deodorant.
Recommendations: Detection on the production of other types Siderophores which having the possibility for diseases treatment.